NEW YORK, NY--(Marketwired - May 15, 2013) - Nuvilex, Inc. (OTCQB: NVLX) has had its living cell encapsulation or "Cell-in-a-Box" technology tested again and again, and each time it has proven it can do exactly what it's intended to do. To date, the proprietary technology has more than impressed and continuously returns remarkable data after each study. In a study not yet discussed, "Cell-in-a-Box" was used to enclose cells that activate more than one anticancer drug simultaneously. This is a form of combination chemotherapy, and using the cell encapsulation technology to achieve the simultaneous reaction has been validated in a preclinical breast cancer study that took place in Germany.

First a little background on combination chemotherapy. It is the use of two or more drugs in parallel or in close sequence to one another during a round of chemotherapy, and this approach is often used to treat various types of cancer, particularly when the disease is at an advanced stage. Combination chemotherapy regimens are often used for cancer that is not responsive to treatment by surgery, radiation, or those that do not (or no longer) respond to treatment with single drugs.

The drugs used in combination chemotherapy regimens are usually used together because each of the drugs in combination "kill" cancer cells in a different way. Therefore, by combining such drugs, it is believed that it's more difficult for the cancer cells to become resistant to treatment over time as they might if only a single drug were to be used. In addition, the drugs used together in combination usually have differences in their side effect (toxicity) profiles.

Continue reading to learn how "Cell-in-a-Box" performed in what is another preclinical study success story at www.stockhousegroup.com/features.

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform that allows CEOs to tell their story through the press with Feature Articles, Research Reports, and CEO Interviews. At the same time, Stock House Group is building a library of Research for Investors to use that allows them to get more informed on small cap stocks. For more information visit Stock House Group at www.stockhousegroup.com.